| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
(S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid does not have a specific pharmacological target. As a natural metabolite with high radical-scavenging activities, it acts as an antioxidant. It may interact with reactive oxygen species (ROS) to neutralize them, thereby protecting cells from oxidative damage. The compound's antioxidant properties suggest potential applications in various industries, including food, pharmaceuticals, and cosmetics, where oxidative stability is desired.
|
|---|---|
| ln Vitro |
In vitro, (S)-3-(4-hydroxyphenyl)-2-hydroxypropionic acid exhibits high DPPH radical-scavenging activity and antioxidant activity. It has high radical-scavenging activities and holds promise as a natural antioxidant. These properties suggest that the compound can effectively neutralize free radicals and protect cells from oxidative stress. However, quantitative data such as IC50 values for antioxidant activity are not readily available.
|
| ln Vivo |
In vivo activity of (S)-3-(4-hydroxyphenyl)-2-hydroxypropionic acid has not been extensively reported. As an antioxidant, it may have potential for protecting against oxidative stress-related diseases. However, no specific in vivo efficacy data are available. The compound is a natural metabolite and is not used as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays for (S)-3-(4-hydroxyphenyl)-2-hydroxypropionic acid would typically involve measuring its antioxidant activity using DPPH, ABTS, or FRAP assays. The compound is incubated with the radical-generating system, and the decrease in absorbance is measured to calculate radical-scavenging activity. For more specific assays, the compound's ability to inhibit lipid peroxidation or protect against oxidative damage to DNA, proteins, or lipids could be assessed. Enzyme inhibition assays (e.g., for COX, LOX) could also be conducted if anti-inflammatory activity is suspected.
|
| Cell Assay |
In vitro cell-based assays for (S)-3-(4-hydroxyphenyl)-2-hydroxypropionic acid involve culturing cells and treating them with the compound to assess its cytoprotective or antioxidant effects. Cells are exposed to an oxidative stressor (e.g., H2O2, UV radiation) in the presence or absence of the compound, and cell viability is assessed using MTT or LDH release assays. Intracellular ROS levels are measured using fluorescent probes such as DCFH-DA. The compound's ability to modulate antioxidant enzyme activity (e.g., SOD, CAT, GPx) can also be assessed.
|
| Animal Protocol |
In vivo animal studies for (S)-3-(4-hydroxyphenyl)-2-hydroxypropionic acid have not been reported in the literature. If conducted, such studies might involve models of oxidative stress, inflammation, or metabolic disorders. Standard protocols for antioxidant studies would involve oral administration in rodents and assessment of oxidative stress markers in blood and tissues. No specific data are available.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of (S)-3-(4-hydroxyphenyl)-2-hydroxypropionic acid have not been characterized. As a small molecule with a molecular weight of 182.17 and multiple hydroxyl groups, it is expected to have good aqueous solubility. The compound may be absorbed orally and undergo metabolism, including glucuronidation and sulfation of the phenolic hydroxyl group. No specific PK data are available.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (S)-3-(4-hydroxyphenyl)-2-hydroxypropionic acid has not been systematically evaluated. As a natural metabolite, it is expected to have low toxicity. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
Reports indicate that (2S)-2-hydroxy-3-(4-hydroxyphenyl)propionic acid has been found in Grossmania henleinii, and relevant data are available for reference.
(S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid is a chiral natural metabolite isolated from Leuconostoc mesenteroides. It has the molecular formula C9H10O4 and a molecular weight of 182.17. The compound exhibits high DPPH radical-scavenging and antioxidant activities and is a key intermediate in catecholamine and thyroid hormone biosynthesis. It is a research compound with potential applications in antioxidant research. The compound is not approved for clinical use. |
| Molecular Formula |
C9H10O4
|
|---|---|
| Molecular Weight |
182.17
|
| Exact Mass |
182.058
|
| CAS # |
23508-35-2
|
| PubChem CID |
9920545
|
| Appearance |
White to off-white solid powder
|
| Density |
1.404g/cm3
|
| Boiling Point |
414.4ºC at 760mmHg
|
| Melting Point |
165-168 °C
|
| Flash Point |
218.6ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
0.38
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
173
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC(=CC=C1C[C@@H](C(=O)O)O)O
|
| InChi Key |
JVGVDSSUAVXRDY-QMMMGPOBSA-N
|
| InChi Code |
InChI=1S/C9H10O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8,10-11H,5H2,(H,12,13)/t8-/m0/s1
|
| Chemical Name |
(2S)-2-hydroxy-3-(4-hydroxyphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (548.94 mM）
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
